Q3 EPS Forecast for Axsome Therapeutics Reduced by Analyst

Key Points

• William Blair has revised its Q3 2025 earnings estimate for Axsome Therapeutics, predicting a loss of ($0.96) per share, a decrease from the previous forecast of ($0.73).
• Despite the lowered earnings expectations, multiple analysts have maintained a positive outlook for Axsome, with a consensus rating of "Buy" and an average price target of $173.13.
• Axsome Therapeutics reported a quarterly EPS of ($0.92), exceeding expectations, with revenue of $150.04 million compared to projections of $140.02 million.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at William Blair decreased their Q3 2025 EPS estimates for shares of Axsome Therapeutics in a research note issued on Monday, August 4th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.96) per share for the quarter, down from their prior estimate of ($0.73). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics' Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($3.62) EPS, Q1 2026 earnings at ($0.43) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at $0.55 EPS, Q4 2026 earnings at $1.23 EPS and FY2026 earnings at $1.33 EPS.

Several other research firms have also recently weighed in on AXSM. Morgan Stanley started coverage on shares of Axsome Therapeutics in a research note on Thursday, July 3rd. They set an "overweight" rating and a $190.00 target price for the company. Robert W. Baird raised their price objective on Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a research report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and issued a $180.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, June 10th. Wells Fargo & Company restated an "overweight" rating and set a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a report on Tuesday, May 6th. Finally, Oppenheimer assumed coverage on Axsome Therapeutics in a research note on Tuesday, June 3rd. They issued an "outperform" rating and a $185.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $178.00.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock traded up $0.48 on Wednesday, hitting $104.80. 311,364 shares of the company traded hands, compared to its average volume of 686,543. Axsome Therapeutics has a 52 week low of $75.56 and a 52 week high of $139.13. The business has a 50-day simple moving average of $105.86 and a 200 day simple moving average of $110.79. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.96 and a current ratio of 1.57. The stock has a market capitalization of $5.23 billion, a P/E ratio of -20.67 and a beta of 0.51.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.08. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%. The company had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million.

Insiders Place Their Bets

In related news, Director Mark Coleman sold 3,750 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total transaction of $395,512.50. Following the transaction, the director directly owned 50,387 shares in the company, valued at approximately $5,314,316.89. This represents a 6.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Hunter R. Murdock sold 7,500 shares of the business's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $100.26, for a total value of $751,950.00. The disclosure for this sale can be found here. Insiders sold 93,437 shares of company stock valued at $9,834,215 over the last three months. 22.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. increased its stake in Axsome Therapeutics by 42.8% in the 1st quarter. Principal Financial Group Inc. now owns 295,671 shares of the company's stock worth $34,484,000 after buying an additional 88,606 shares during the period. Penserra Capital Management LLC bought a new position in Axsome Therapeutics in the 1st quarter worth about $2,229,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Axsome Therapeutics by 20.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company's stock worth $4,877,000 after acquiring an additional 9,928 shares during the period. Trek Financial LLC bought a new stake in shares of Axsome Therapeutics during the first quarter valued at approximately $3,446,000. Finally, Edgestream Partners L.P. bought a new stake in shares of Axsome Therapeutics during the first quarter valued at approximately $8,174,000. 81.49% of the stock is owned by institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.